[EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE L'HEPATITE C
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2004103996A1
公开(公告)日:2004-12-02
Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
[EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA REPLICATION DU VIRUS DE L'IMMUNODEFICIENCE HUMAINE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2010130034A1
公开(公告)日:2010-11-18
Compounds of formula I wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.
式I中的化合物,其中a、R1、R2、R3、R4、R5和R6如本文所定义,可用作HIV复制抑制剂。
Compounds, compositions and methods
申请人:Morgan P. Bradley
公开号:US20070066626A1
公开(公告)日:2007-03-22
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.